Astrazeneca Stock Analysis

AZN -  USA Stock  

USD 57.24  0.40  0.69%

The modest gains experienced by current holders of Astrazeneca Plc could raise concerns from institutional investors as the firm it trading at a share price of 57.24 on 7,065,556 in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in June. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.12. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Astrazeneca Plc stock analysis report makes it easy to digest most publicly released information about Astrazeneca Plc and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Astrazeneca Stock analysis module also helps to analyze the Astrazeneca Plc price relationship with some important fundamental indicators such as market cap and management efficiency.

Astrazeneca Stock Analysis Notes

About 17.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.83. Astrazeneca Plc ADR next dividend is scheduled to be issued on the 25th of February 2021. The entity had 2:1 split on the 27th of July 2015. AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 76100 people. For more info on Astrazeneca Plc ADR please contact Pascal Soriot at (44) 1223 352 858 or go to www.astrazeneca.com.

Astrazeneca Plc Quarterly Cost of Revenue

1.86 BillionShare

Astrazeneca Plc ADR Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Astrazeneca Plc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Astrazeneca Plc ADR or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company has 22.49 B in debt with debt to equity (D/E) ratio of 1.56, which is OK given its current industry classification. Astrazeneca Plc ADR has a current ratio of 0.85, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
Astrazeneca Plc ADR has a strong financial position based on the latest SEC filings
Latest headline from www.equities.com: Astrazeneca falls 1.13 percent on Moderate Volume July 28 - Equities.com

Astrazeneca Plc ADR Upcoming and Recent Events

Earnings reports are used by Astrazeneca Plc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Astrazeneca Plc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of July 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Astrazeneca Largest EPS Surprises

Earnings surprises can significantly impact Astrazeneca Plc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2002-10-24
2002-09-300.180.20.0211 
1999-10-29
1999-09-300.170.190.0211 
2005-04-28
2005-03-310.290.320.0310 
View All Earnings Estimates

Astrazeneca Plc SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Astrazeneca Plc prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Astrazeneca Plc investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Astrazeneca Plc ADR specific information freely available to individual and institutional investors to make a timely investment decision.
27th of July 2021
Unclassified Corporate Event
View
26th of July 2021
Other Events
View
22nd of July 2021
Other Events
View
21st of July 2021
Other Events
View
19th of July 2021
Other Events
View
16th of July 2021
Other Events
View
14th of July 2021
Other Events
View
8th of July 2021
Other Events
View

Astrazeneca Plc Thematic Classifications

In addition to having Astrazeneca Plc stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French
Drugs IdeaDrugs
Drug manufacturing and delivery

Astrazeneca Market Capitalization

The company currently falls under 'Mega-Cap' category with total capitalization of 151.97 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Astrazeneca Plc's market, we take the total number of its shares issued and multiply it by Astrazeneca Plc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Astrazeneca Profitablity

Astrazeneca Plc's profitability indicators refer to fundamental financial ratios that showcase Astrazeneca Plc's ability to generate income relative to its revenue or operating costs. If, let's say, Astrazeneca Plc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Astrazeneca Plc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Astrazeneca Plc's profitability requires more research than a typical breakdown of Astrazeneca Plc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 14.42 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 24.4 %, which entails that for every 100 dollars of revenue, it generated 0.24 of operating income.
Last ReportedProjected for 2021
Return on Investment 11.99  15.99 
Return on Average Assets 0.05  0.06 
Return on Average Equity 0.25  0.22 
Return on Invested Capital 0.20  0.24 
Return on Sales 0.20  0.19 

Management Efficiency

The entity has Return on Asset of 4.19 % which means that on every $100 spent on asset, it made $4.19 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 29.67 %, implying that it generated $29.67 on every 100 dollars invested. Astrazeneca Plc management efficiency ratios could be used to measure how well astrazeneca plc adr manages its routine affairs as well as how well it operates its assets and liabilities. Astrazeneca Plc Return on Investment is quite stable at the moment as compared to the past year. The company's current value of Return on Investment is estimated at 15.99. Return on Average Assets is expected to rise to 0.06 this year, although the value of Return on Average Equity will most likely fall to 0.22. Astrazeneca Plc Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 66.33 Billion
Last ReportedProjected for 2021
Book Value per Share 5.95  6.12 
Enterprise Value over EBIT 28.00  28.21 
Enterprise Value over EBITDA 17.37  16.27 
Price to Book Value 8.40  7.42 
Tangible Assets Book Value per Share 12.93  11.43 
Enterprise Value145.4 B131.8 B
Tangible Asset Value33.9 B29.9 B

Technical Drivers

As of the 30th of July, Astrazeneca Plc shows the Downside Deviation of 1.3, risk adjusted performance of 0.0972, and Mean Deviation of 0.8478. Astrazeneca Plc ADR technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Astrazeneca Plc ADR, which can be compared to its rivals. Please confirm Astrazeneca Plc ADR variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Astrazeneca Plc ADR is priced correctly, providing market reflects its regular price of 57.24 per share. Given that Astrazeneca Plc has jensen alpha of 0.1301, we suggest you to validate Astrazeneca Plc ADR's prevailing market performance to make sure the company can sustain itself at a future point.

Astrazeneca Plc ADR Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Astrazeneca Plc middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Astrazeneca Plc ADR. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Astrazeneca Plc Outstanding Bonds

Astrazeneca Plc issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Astrazeneca Plc ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Astrazeneca bonds can be classified according to their maturity, which is the date when Astrazeneca Plc ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MaturityCouponRating
ASTRAZENECA PLC 64509/15/20376.45
AA-
ASTRAZENECA PLC 409/18/20424.0
AA-
ZENECA WILMINGTON INC11/15/20237.0
AA-

Astrazeneca Plc Technical and Predictive Indicators

Astrazeneca Plc Forecast Models

Astrazeneca Plc time-series forecasting models is one of many Astrazeneca Plc's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Astrazeneca Plc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Astrazeneca Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Astrazeneca Plc stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Astrazeneca shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Astrazeneca Plc. By using and applying Astrazeneca Stock analysis, traders can create a robust methodology for identifying Astrazeneca entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin 14.87  19.22 
EBITDA Margin 0.31  0.30 
Gross Margin 0.80  0.76 
Profit Margin 0.12  0.12 
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 76100 people.

Current Astrazeneca Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Astrazeneca analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Astrazeneca analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
66.72Buy4Odds
Astrazeneca Plc ADR current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Astrazeneca analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Astrazeneca stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Astrazeneca Plc ADR, talking to its executives and customers, or listening to Astrazeneca conference calls.
Astrazeneca Analyst Advice Details

Astrazeneca Stock Analysis Indicators

Astrazeneca Plc ADR stock analysis indicators help investors evaluate how Astrazeneca Plc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Astrazeneca Plc shares will generate the highest return on investment. By understating and applying Astrazeneca Plc stock analysis, traders can identify Astrazeneca Plc position entry and exit signals to maximize returns.
Quick Ratio0.67
Trailing Annual Dividend Rate2.80
Fifty Two Week Low46.48
Revenue Growth15.20%
Payout Ratio92.41%
Average Daily Volume Last 10 Day34.77M
Shares Short Prior Month125.41M
Average Daily Volume In Three Month10.64M
Earnings Growth100.00%
Shares Percent Shares Out5.15%
Earnings Quarterly Growth100.10%
Gross Margins79.40%
Forward Price Earnings13.82
Float Shares2.61B
Fifty Two Week High60.93
Fifty Day Average58.62
Enterprise Value To Ebitda25.54
Two Hundred Day Average53.42
Enterprise Value To Revenue6.23
Trailing Annual Dividend Yield4.93%
Please continue to Trending Equities. Note that the Astrazeneca Plc ADR information on this page should be used as a complementary analysis to other Astrazeneca Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Astrazeneca Stock analysis

When running Astrazeneca Plc ADR price analysis, check to measure Astrazeneca Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astrazeneca Plc is operating at the current time. Most of Astrazeneca Plc's value examination focuses on studying past and present price action to predict the probability of Astrazeneca Plc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Astrazeneca Plc's price. Additionally, you may evaluate how the addition of Astrazeneca Plc to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
The market value of Astrazeneca Plc ADR is measured differently than its book value, which is the value of Astrazeneca that is recorded on the company's balance sheet. Investors also form their own opinion of Astrazeneca Plc's value that differs from its market value or its book value, called intrinsic value, which is Astrazeneca Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astrazeneca Plc's market value can be influenced by many factors that don't directly affect Astrazeneca Plc ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astrazeneca Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine Astrazeneca Plc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astrazeneca Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.